Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone

Luciano J. Costa, MD PhD, Nicholas Burwick, MD, Andrzej Jakubowiak, MD PhD, Jonathan L. Kaufman, MD, Fernando Cabanillas, MD, Monique Dail, PhD, Sudeep Karve, Abdullah A. Masud, PhD, Xiaoqing Yang, PhD, Orlando F. Bueno, Sarah Mudd, PhD, Jeremy A. Ross, Faith E. Davies

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-134737

Published: 2020

Journal Articles

Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma

Blood (2015) 126 (23): 3961.

https://doi.org/10.1182/blood.V126.23.3961.3961

Published: 2015

Journal Articles

Clinically Discordant Indolent Lymphomas: A Subset of Indolent NHLs with a Less Favorable Prognosis and Propensity to Transform

Fernando Cabanillas, MD, Noridza Rivera, MD, Orestes Pavia, MD, Wandaly I. Pardo, MD, Margarita Bruno, MD

Blood (2015) 126 (23): 1497.

https://doi.org/10.1182/blood.V126.23.1497.1497

Published: 2015

Journal Articles

Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo ® ) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas

Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Steven R. Deitcher, MD, Anas Younes, MD, Luis Fayad, MD, Andre Goy, MD, Nam H. Dang, MD, PhD, A Forman, MD, Peter McLaughlin, MD, Barbara Pro, MD, Jorge Enrique Romaguera, Felipe Samaniego, MD, Jeffrey A. Silverman, Ph.D., Andreas H. Sarris, MD, PhD, Fernando Cabanillas, MD

Blood (2013) 122 (21): 3033.

https://doi.org/10.1182/blood.V122.21.3033.3033

Published: 2013

Journal Articles

The Pretreatment Absolute Lymphocyte Count (ALC), but Not the Absolute Monocyte Count (AMC) or ALC/AMC Ratio, Is an Independent Prognostic Factor in Aggressive Non-Hodgkin Lymphoma (aNHL)

Noridza Rivera-Rodriguez, MD, Fernando Cabanillas, MD, Carlos Montalban, Jose Francisco Tomas, MD, María José Terol, MD, PhD, Armando López-Guillermo, MD, Wandaly I. Pardo, MD, Orestes A. Pavia, MD, Margarita Bruno, MD, Karen Janice Santiago, Pablo Guisado-Vasco, MD, PhD, Angel Ruedas, MD, Raquel de Oña, Silvia Solorzano, Ana Isabel Teruel, MD, Laura Garcia-Sanchis, Jordina Rovira, MD, Ivan Dlouhy

Blood (2012) 120 (21): 1596.

https://doi.org/10.1182/blood.V120.21.1596.1596

Published: 2012

Journal Articles

Single Nucleotide Polymorphisms (SNPs) in Genes for Glutathione-Related Metabolism, Cyclin D1, and DNA Repair As Predictive Biomarkers in Mantle Cell Lymphoma Patients Treated with R-HyperCVAD with Ten Year Clinical Follow-up,

Michael A. Thompson, MD, PhD, Caimiao Wei, PhD, Ann M Moyer, PhD, Julie M Cunningham, PhD, Luhua Wang, MD, Luis Fayad, MD, Lei Feng, Ph.D, Maria Alma Rodriguez, MD, Fernando Cabanillas, MD, Hagop M. Kantarjian, Larry W Kwak, MD, PhD, Jorge E Romaguera, MD

Blood (2011) 118 (21): 3650.

https://doi.org/10.1182/blood.V118.21.3650.3650

Published: 2011

Journal Articles

Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.

Michael Craig, MD, Wahid T Hanna, MD, Fernando Cabanillas, MD, Chien-Shing Chen, MD, PhD, Sudha Parasuraman, MD, Rachel Neuwirth, MS, Owen A. O'Connor, MD, PhD

Blood (2010) 116 (21): 2798.

https://doi.org/10.1182/blood.V116.21.2798.2798

Published: 2010

Journal Articles

Phase I-II Study of Dose Dense PEG-Filgrastim and GM-CSF as Support for Dose Dense CHOP-R Front Line Therapy for Aggressive Non-Hodgkin's Lymphoma (NHL).

Maribel Cotto, MD, Fernando Cabanillas, MD, Idalia Liboy, MD, Ezequiel Rivera, MD, Orestes A. Pavia, MD, Margarita Bruno

Blood (2010) 116 (21): 2789.

https://doi.org/10.1182/blood.V116.21.2789.2789

Published: 2010

Journal Articles

A Phase II Study of Gemcitabine, Rituximab, and Oxaliplatin In Combination for Relapsed/Refractory Non-Hodgkin's Lymphomas

Jennifer L. Cultrera, MD, Jijun Liu, MD, Idalia Liboy, MD, Celeste M. Bello, MD, Lubomir Sokol, MD, PhD, Eduardo M. Sotomayor, MD, Enrique Santana, RN, Fernando Cabanillas, MD

Blood (2010) 116 (21): 2879.

https://doi.org/10.1182/blood.V116.21.2879.2879

Published: 2010

Journal Articles

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Luhua Wang, MD, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Barry Samuels, MD, Qing Yi, MD, PhD, Barbara Pro, MD, Michelle Fanale, M.D., Jatin Shah, MD, Anas Younes, MD, Neda Bell, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Fernando Cabanillas, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 2719.

https://doi.org/10.1182/blood.V114.22.2719.2719

Published: 2009

Journal Articles

The Baseline PET SUV Correlates Better with Clinical Outcome Than the Post-Therapy PET Scan in Previously Untreated Patients with Histologically Aggressive Non-Hodgkin Lymphoma (NHL)

Fernando Cabanillas, MD, Jorge Toro, Jorge Perdomo, Orestes Pavia, Idalia Liboy, Clara Salgado, Viviana Freire, Ezequiel Rivera, Norman Maldonado

Blood (2008) 112 (11): 3588.

https://doi.org/10.1182/blood.V112.11.3588.3588

Published: 2008

Journal Articles

Marginal Zone Lymphoma: Factors That Affect the Final Outcome, a Study of 275 Patients

Ali Mazloom, MD, Valerie K Reed, MD, Fernando Cabanillas, MD, Luis Fayad, MD, Barbara Pro, M.D., Puneeth Iyengar, MD, PhD, Peter McLaughlin, MD, Diana L Urbauer, MS, Bouthaina S. Dabaja, MD

Blood (2008) 112 (11): 3764.

https://doi.org/10.1182/blood.V112.11.3764.3764

Published: 2008

Journal Articles

Diffuse Large Cell Lymphoma Transformed from Rosai-Dorfman Disease

David Jendiroba, MD, PhD, Marcus Magnus Sampaio, MD, MS, Márcia Vilela Gonçalves, MD, Juliana Alves Rodrigues, RN, Daniella Barqueti Jendiroba, MD, Fernando Cabanillas, MD

Blood (2008) 112 (11): 4968.

https://doi.org/10.1182/blood.V112.11.4968.4968

Published: 2008

Journal Articles

R-HCVAD/R-MTX-ARAC Is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years

Luis Fayad, MD, Barbara Pro, MD, Fredrick Hagemeister, MD, Fernando Cabanillas, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Michael Wang, MD, Sattva Neelapu, MD, Larry Kwak, MD, PhD, Jorge Romaguera, MD, Maria A. Rodriguez, MD

Blood (2007) 110 (11): 1285.

https://doi.org/10.1182/blood.V110.11.1285.1285

Published: 2007

Journal Articles

The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone

Michael J. Overman, MD, Lei Feng, MS, Barbara Pro, MD, Peter McLaughlin, MD, Mark Hess, BBA, Felipe Samaniego, MD, Anas Younes, MD, Jorge E. Romaguera, MD, Frederick B. Hagemeister, MD, Larry Kwak, MD, PhD, Fernando Cabanillas, MD, Maria A. Rodriguez, MD, Luis E. Fayad, MD

Blood (2007) 110 (11): 1289.

https://doi.org/10.1182/blood.V110.11.1289.1289

Published: 2007

Journal Articles

Very Early Post-Treatment PET/CT Scan Performed One Week after First Chemotherapy Course Compared Against the Standard PET after Third Course in Histologically Aggressive Lymphoma (NHL).

Fernando Cabanillas, MD, Jorge Toro, MD, Jorge W. Perdomo, MD, Idalia Liboy, MD, Orestes Pavia, MD, Norman Maldonado, MD, Ezequiel Rivera, MD

Blood (2006) 108 (11): 2433.

https://doi.org/10.1182/blood.V108.11.2433.2433

Published: 2006

Journal Articles

High Incidence of Non-Neutropenic Infections Induced by Rituximab Plus Chemotherapy and Associated with Hypogammaglobulinemia: A Frequently Unrecognized and Easily Treatable Complication.

Fernando Cabanillas, MD, Orestes Pavia, MD, Ezequiel Rivera, MD

Blood (2005) 106 (11): 2445.

https://doi.org/10.1182/blood.V106.11.2445.2445

Published: 2005

Journal Articles

High (95%) Response Rates in Relapsed/Refractory Mantle Cell Lymphoma after R-HCVAD Alternating with R-Methotrexate/Cytarabine (R-M-A).

Jorge Enrique Romaguera, MD, Luis E. Fayad, MD, Michael Wang, MD, Fernando Cabanillas, MD, Fredrick Hagemeister, MD, Peter McLaughlin, MD, Alma Rodriguez, MD, Anas Younes, MD, Sattva Neelapu, MD, Andre H. Goy, MD, Virginia Beasley, Larry Kwak, MD, PhD

Blood (2005) 106 (11): 2446.

https://doi.org/10.1182/blood.V106.11.2446.2446

Published: 2005

Journal Articles

Time to Treatment Failure (TTF) and FLIPI Correlate Well with Survival and Are Independent Variables in Stage IV Indolent Follicular Lymphomas (IFL).

Luis Fayad, MD, Barbara Pro, MD, Qi Liu, MD, PhD, Mark Hess, Fredrick Hagemeister, MD, Jorge Romaguera, MD, Felipe Samaniego, MD, Fernando Cabanillas, MD, Alma Rodriguez, MD, Anas Younes, MD, Michael Wang, MD, Peter McLaughlin, MD

Blood (2005) 106 (11): 933.

https://doi.org/10.1182/blood.V106.11.933.933

Published: 2005

Journal Articles

Chemo-Immunotherapy with Hyper-CVAD Plus Ritixumab for Adult Burkitt’s and Burkitt’s Type Lymphoma (BL) or Acute Lymphoblastic Leukemia (B-ALL).

Deborah A. Thomas, MD, Stefan Faderl, MD, Susan O’Brien, MD, Carlos Bueso-Ramos, MD, Jorge Cortes, MD, Guillermo Garcia-Manero, MD, Francis Giles, MD, Srdan Verstovsek, MD, PhD, William Wierda, MD, PhD, Sherry Pierce, RN, Jiaquin Shan, Mark Brandt, Fredrick Hagemeister, MD, Fernando Cabanillas, MD, Michael J. Keating, MD, Hagop Kantarjian, MD

Blood (2005) 106 (11): 149.

https://doi.org/10.1182/blood.V106.11.149.149

Published: 2005

NARROW

Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone

Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma

Clinically Discordant Indolent Lymphomas: A Subset of Indolent NHLs with a Less Favorable Prognosis and Propensity to Transform

Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo ® ) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas

The Pretreatment Absolute Lymphocyte Count (ALC), but Not the Absolute Monocyte Count (AMC) or ALC/AMC Ratio, Is an Independent Prognostic Factor in Aggressive Non-Hodgkin Lymphoma (aNHL)

Single Nucleotide Polymorphisms (SNPs) in Genes for Glutathione-Related Metabolism, Cyclin D1, and DNA Repair As Predictive Biomarkers in Mantle Cell Lymphoma Patients Treated with R-HyperCVAD with Ten Year Clinical Follow-up,

Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.

Phase I-II Study of Dose Dense PEG-Filgrastim and GM-CSF as Support for Dose Dense CHOP-R Front Line Therapy for Aggressive Non-Hodgkin's Lymphoma (NHL).

A Phase II Study of Gemcitabine, Rituximab, and Oxaliplatin In Combination for Relapsed/Refractory Non-Hodgkin's Lymphomas

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

The Baseline PET SUV Correlates Better with Clinical Outcome Than the Post-Therapy PET Scan in Previously Untreated Patients with Histologically Aggressive Non-Hodgkin Lymphoma (NHL)

Marginal Zone Lymphoma: Factors That Affect the Final Outcome, a Study of 275 Patients

Diffuse Large Cell Lymphoma Transformed from Rosai-Dorfman Disease

R-HCVAD/R-MTX-ARAC Is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years

The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone

Very Early Post-Treatment PET/CT Scan Performed One Week after First Chemotherapy Course Compared Against the Standard PET after Third Course in Histologically Aggressive Lymphoma (NHL).

High Incidence of Non-Neutropenic Infections Induced by Rituximab Plus Chemotherapy and Associated with Hypogammaglobulinemia: A Frequently Unrecognized and Easily Treatable Complication.

High (95%) Response Rates in Relapsed/Refractory Mantle Cell Lymphoma after R-HCVAD Alternating with R-Methotrexate/Cytarabine (R-M-A).

Time to Treatment Failure (TTF) and FLIPI Correlate Well with Survival and Are Independent Variables in Stage IV Indolent Follicular Lymphomas (IFL).

Chemo-Immunotherapy with Hyper-CVAD Plus Ritixumab for Adult Burkitt’s and Burkitt’s Type Lymphoma (BL) or Acute Lymphoblastic Leukemia (B-ALL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only